CXCL13 and liver disorder: Looking forward, we anticipate biomarker-enriched, site-aware trials for MSS-iCMS3 that integrate (i) boundary-centric spatial biomarkers (e.g., LAMP3+ dendritic cell-CXCL13+ T-cell niches) as pharmacodynamic readouts, (ii) organ-stratified eligibility (non-liver vs. liver disease), and (iii) mechanism-driven combinations such as angiogenesis modulators, DC/myeloid agents, and T-cell engagers [4,28,33,36].